Just as importantly, the addition of extra ingredients creates a formulation that differs from the branded products, which compounders may use as a legal justification to avoid producing an outright copy of a brand-name drug.Recall Initiation Date: July 18, 2025Link: FDA Enforcement Report Semaglutide Company: Boothwyn Pharmacy, LLC (licensed compounding pharmacy)Location: Kennett Square, PennsylvaniaScope: Semaglutide, 2.5 mg/mL injection: .8 mL (186 vials), 2 mL (642 vials), 4 mL (648 vials)Drug Description: Treats type 2 diabetes and obesityRecall Reason: Subpotent drugs (which means they less than the specified amount of active ingredient)Recall Initiation Date: July 9, 2025Link: FDA Enforcement Report Semaglutide, Semaglutide/Cyanocobalamin, Tirzepatide, Tirzepatide/Cyanocobalamin Company: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)Location: Englewood, ColoradoScope: Semaglutide: 5 mg/mL (164 pre-filled syringes)
Hydrophobic and hydrophilic materials Hydrophobic (water fearing) materials dont like water and try to keep their distance
Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes
In summary, this study proposes an innovative therapeutic strategy that not only provides novel insights into the clinical potential and pharmacological mechanisms of GLP-1RAs in RA but also establishes a new cartilage-protective insight that challenges the prevailing synovium-centric approach to RA therapy
A blocked methylation cycle can also become a detoxification problem
)
)
